CSPG4 and acute myeloid leukemia: For instance, effectiveness of immunotargeting NG2/CSPG4 in solid tumours, both “passively” and “actively” (with a wealth of agents and approaches), has been appreciated and therefore transposition of these targeting approaches to B-ALL and discrete AML variants would seem implicit.